Literature DB >> 8643810

A new attack on smoking using an old-time remedy.

M C Moore, C J Mikhail.   

Abstract

This article first will explain the reasons behind and goals of state recoupment actions against the major cigarette manufacturers, their lobbying arm and trade association, and their public relations firms (collectively referred to as the "tobacco industry") for the recovery of Medicaid and other indigent care expenditures on smoking-related illnesses. These are, primarily, to relieve the heavy financial burden on state treasuries and to stop the tobacco industry from targeting children in advertising and promotions. To put this new legal approach in perspective, the article presents a brief historical background to the tobacco industry's litigation strategy: to wear down opponents through delay and intimidation, to cast doubt on science, and to wrongfully invoke the attorney-client privilege against disclosure of incriminating evidence. Next authors discuss the states' strategy: each filing one suit seeking equitable remedies under theories of restitution/unjust enrichment, indemnity, public nuisance, and injunctive relief to protect the interests of minors, instead of maintaining thousands of product liability claims on behalf of individual smokers. This will be followed by a critique of the industry's response to state actions: political attacks against attorneys general and trial lawyers and charges that the lawsuits would hurt business as well as a variety of legal challenges, including an imaginative but risky defense that if smoking indeed causes disease and attendant health care expenditures, then the tobacco industry ought to be given a credit against those expenditures for the taxes generated by its business and the "savings" which inure to the states from the premature deaths of smokers (the cost of geriatric care, for example). The article will wrap up by impressing on health officials and other readers what is at stake in these actions and what their success or failure will mean for the Medicaid program.

Entities:  

Mesh:

Year:  1996        PMID: 8643810      PMCID: PMC1381760     

Source DB:  PubMed          Journal:  Public Health Rep        ISSN: 0033-3549            Impact factor:   2.792


  3 in total

1.  Lipid molecular species retailoring and membrane fluidity.

Authors:  G A Thompson
Journal:  Biochem Soc Trans       Date:  1989-04       Impact factor: 5.407

2.  Actual causes of death in the United States.

Authors:  J M McGinnis; W H Foege
Journal:  JAMA       Date:  1993-11-10       Impact factor: 56.272

3.  The economic implications of tobacco product sales in a nontobacco state.

Authors:  K E Warner; G A Fulton
Journal:  JAMA       Date:  1994-03-09       Impact factor: 56.272

  3 in total
  5 in total

1.  How organized medical care can advance public health.

Authors:  A Robbins; P Freeman
Journal:  Public Health Rep       Date:  1999 Mar-Apr       Impact factor: 2.792

2.  Winning against big tobacco. Let's take the time to get it right.

Authors:  H H Humphrey
Journal:  Public Health Rep       Date:  1997 Sep-Oct       Impact factor: 2.792

3.  State estimates of Medicaid expenditures attributable to cigarette smoking, fiscal year 1993.

Authors:  L S Miller; X Zhang; T Novotny; D P Rice; W Max
Journal:  Public Health Rep       Date:  1998 Mar-Apr       Impact factor: 2.792

4.  A year of living dangerously: the tobacco control community meets the global settlement.

Authors:  M Bloch; R Daynard; R Roemer
Journal:  Public Health Rep       Date:  1998 Nov-Dec       Impact factor: 2.792

Review 5.  Economics on trial: the use and abuse of economic methods in third party tobacco litigation.

Authors:  Wendy Max; Theo Tsoukalas
Journal:  Tob Control       Date:  2006-12       Impact factor: 7.552

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.